Bryce Point Capital LLC Invests $451,000 in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Bryce Point Capital LLC acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,719 shares of the biopharmaceutical company’s stock, valued at approximately $451,000.

Other institutional investors have also made changes to their positions in the company. Franklin Resources Inc. grew its holdings in Ultragenyx Pharmaceutical by 95.2% during the fourth quarter. Franklin Resources Inc. now owns 427,359 shares of the biopharmaceutical company’s stock valued at $17,979,000 after purchasing an additional 208,456 shares during the last quarter. Alliancebernstein L.P. grew its stake in Ultragenyx Pharmaceutical by 5.3% in the 4th quarter. Alliancebernstein L.P. now owns 1,627,932 shares of the biopharmaceutical company’s stock valued at $68,487,000 after buying an additional 81,667 shares during the last quarter. California Public Employees Retirement System raised its holdings in Ultragenyx Pharmaceutical by 15.1% in the 4th quarter. California Public Employees Retirement System now owns 131,344 shares of the biopharmaceutical company’s stock worth $5,526,000 after acquiring an additional 17,225 shares during the period. Schroder Investment Management Group lifted its position in Ultragenyx Pharmaceutical by 105.7% during the 4th quarter. Schroder Investment Management Group now owns 376,161 shares of the biopharmaceutical company’s stock worth $15,900,000 after acquiring an additional 193,296 shares during the last quarter. Finally, DnB Asset Management AS boosted its holdings in Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. DnB Asset Management AS now owns 12,132 shares of the biopharmaceutical company’s stock valued at $510,000 after acquiring an additional 1,889 shares during the period. 97.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on RARE shares. Canaccord Genuity Group lifted their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Wells Fargo & Company increased their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research report on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Finally, Wedbush reissued a “neutral” rating and issued a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $92.79.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,990 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $42.88, for a total value of $128,211.20. Following the transaction, the executive vice president now directly owns 54,991 shares in the company, valued at approximately $2,358,014.08. This trade represents a 5.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Theodore Alan Huizenga sold 967 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $40,710.70. Following the sale, the chief accounting officer now owns 50,265 shares of the company’s stock, valued at approximately $2,116,156.50. The trade was a 1.89 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 124,643 shares of company stock worth $5,256,268. 5.80% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ:RARE opened at $32.43 on Friday. The company has a market capitalization of $3.04 billion, a PE ratio of -5.12 and a beta of 0.61. The company’s fifty day moving average is $40.83 and its 200-day moving average is $46.10. Ultragenyx Pharmaceutical Inc. has a 52 week low of $32.07 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The firm had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. On average, analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.